AffiliationDepartment of Immunology, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.
MetadataShow full item record
AbstractThe relative susceptibility of 10 human leukaemias comprising acute phase leucocytes from 5 acute myeloid and 5 lymphoid neoplasms, and 2 immunoblastic lymphomas to killing by peripheral blood mononuclear cells (PBMC), before and after target cell treatment with phytohaemagglutinin (PHA), and by interleukin-2 (IL-2) activated peripheral blood lymphocytes (PBL) was investigated in short term 51Cr release assays using effector cells from 10 allogeneic donors. Optimal lectin-dependent cellular cytotoxicity (LDCC) was verified against K562 and L1210 cells and lymphokine-activated killing (LAK) against K562 and Daudi cells. Under these conditions, the majority of the leukaemias tested revealed only a finite sensitivity to any of the cytotoxic mechanisms, which was dependent on the donor origin of the effectors. The leukaemias were more consistently susceptible to LDCC than LAK and removal of adherent cells to enrich for the latter activity in effector populations, was ineffective. Lymphocytes from a patient in long term (greater than 5 yr) remission exhibited LAK against the autologous target E84, a natural killer (NK)-sensitive acute myelomonocytic leukaemia. These cells failed to cross-compete for lysis of K562 by LAK cells, suggesting the existence of different recognition structure(s) on the two targets.
CitationLymphokine activated killing of fresh human leukaemias. 1986, 10 (6):683-8 Leuk Res
- LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
- Authors: Hermann GG, Zeuthen J, Claësson MH
- Issue date: 1992 Jan-Feb
- VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
- Authors: Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG
- Issue date: 1995 Dec
- Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
- Authors: Wiebke EA, Custer MC, Rosenberg SA, Lotze MT
- Issue date: 1990 Apr
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
- Authors: Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA
- Issue date: 1982 Jun 1
- Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
- Authors: Teichmann JV, Ludwig WD, Thiel E
- Issue date: 1992 May-Jun